TCR-T Cells in the Treatment of Advanced Pancreatic Cancer

Inclusion Criteria: * To be eligible for the study, patients must meet all of the following criteria: 1. Male or female, aged 18-75 years; 2. Patients with advanced pancreatic cancer diagnosed by histology or cytology, patients who failed to respond to standard treatment, relapsed or voluntarily gave up; 3. Patients must have tumor tissue that expresses specific tumor antigens, such as mutations in RAS and/or TP53; 4. Patients must undergo HLA matching testing and meet the requirements of HLA matching. 5. At least one measurable or evaluable lesion ≥15 mm according to RECIST1.1 criteria; 6. Patients with ECOG \< 2 and life expectancy ≥3 months; 7. a) Liver function: ALT/AST \< 3 times the upper limit of normal value (ULN) and bilirubin ≤34.2μmol/L; b) renal function: creatinine \< 220μmol/L; c) terminal oxygen saturation ≥95% in room air; d) Cardiac function: left ventricular ejection fraction (LVEF) ≥60%; e) Blood routine: absolute neutrophil count ≥ 1×109/L; Platelet count ≥70×109/L; Absolute lymphocyte count ≥100 cells /μL; 8. The patients met the requirements of apheresis without any contraindications. 9. Women of childbearing age who have a negative urine pregnancy test at screening and before starting dosing and who have agreed to use highly effective contraception for at least 100 days after infusion; Female participants must agree not to donate eggs (oocytes, oocytes) for assisted reproductive purposes during the study and for 90 days after receiving the last study drug; 10. Male subjects with a fertile partner must consent to use an effective barrier method of contraception for at least 100 days after infusion; Must agree not to donate sperm for at least one year; 11. Sign an informed consent form. Exclusion Criteria: * Patients who met any of the following criteria were not eligible for inclusion in the study: 1. Persons with severe mental disorders; 2. A positive virological test for any of the following: HIV; HCV; HBsAg; HBcAb was positive, and HBV DNA copy number and TPPA were positive. 3. Patients with severe allergic history or allergic constitution; 4. Severe underlying medical conditions such as evidence of other serious active viral, bacterial or uncontrolled systemic fungal infection; Active autoimmune disease or a history of autoimmune disease within 3 years; 5. A history of autoimmune diseases (e.g., Crohn's disease, rheumatoid arthritis, systemic lupus erythematosus) leading to end-organ damage or requiring systemic immunosuppressive/systemic disease modulating drugs within the past 2 years; 6. Combined with organ dysfunction, such as renal insufficiency; 7. Had been enrolled in another clinical trial within 4 weeks before enrollment in the trial; 8. Those who were unable to comply with the study protocol and follow-up plan due to physiological, family, social, geographical and other factors; 9. Patients with contraindications to cyclophosphamide or fludarabine chemotherapy; 10. Subjects who required additional immunosuppressive drug therapy within 72 hours before TCR-T infusion, except for the treatment of adverse events during the trial; 11. Pregnant, lactating women, or men who plan to have children while participating in the study or within 100 days of receiving study treatment; 12. Any other condition considered by the investigator to be ineligible for enrollment.